Sermorelin vs CJC-1295: Growth Hormone Secretagogue Comparison

Sermorelin and CJC-1295 are both growth hormone-releasing hormone (GHRH) analogs — peptides that stimulate the pituitary gland to produce and release growth hormone. However, they differ significantly in structure, half-life, and research applications. Understanding these differences is essential for researchers working with the growth hormone axis.

How Do They Compare?

Sermorelin (GHRH 1-29) is a truncated version of natural GHRH, containing the first 29 of the original 44 amino acids. It has a short half-life of approximately 10-20 minutes, which means it produces a rapid, physiological pulse of GH release that closely mimics the body’s natural secretion pattern (PMID: 9467527).

CJC-1295 exists in two forms: CJC-1295 without DAC (also called Modified GRF 1-29 or “CJC-1295 No DAC”) and CJC-1295 with DAC (Drug Affinity Complex). Both are based on the GHRH 1-29 sequence but with amino acid substitutions at positions 2, 8, 15, and 27 that protect against enzymatic degradation. The “No DAC” version has a half-life of approximately 30 minutes, while the “with DAC” version binds to albumin in the bloodstream, extending its half-life to 6-8 days (PMID: 16352683).

This half-life difference is the critical distinction: Sermorelin creates brief, natural GH pulses; CJC-1295 No DAC creates slightly extended pulses; CJC-1295 with DAC creates sustained, elevated GH levels over days.

Key Research Highlights

Pulsatile vs Sustained: Sermorelin preserves natural pulsatile GH release. CJC-1295 with DAC produces sustained elevation, which may have different physiological implications in research models (PMID: 16352683).

IGF-1 Response: CJC-1295 with DAC produced sustained IGF-1 elevation for 6-14 days after a single administration, whereas Sermorelin’s IGF-1 effects are transient.

Combination Research: CJC-1295 No DAC is frequently studied in combination with Ipamorelin (a GHRP), as the GHRH + GHRP pairing targets complementary receptors on pituitary somatotrophs.

Clinical History: Sermorelin has a longer clinical research history, having been FDA-approved as a diagnostic agent. CJC-1295 research is more recent but demonstrates greater potency per administration.

Quick Reference

Property	Sermorelin	CJC-1295 No DAC	CJC-1295 with DAC
Sequence Base	GHRH 1-29	Modified GHRH 1-29	Modified GHRH 1-29 + DAC
Half-Life	10-20 min	~30 min	6-8 days
GH Pattern	Natural pulse	Extended pulse	Sustained elevation
IGF-1 Duration	Hours	Hours	6-14 days
Common Pairing	Standalone	+ Ipamorelin	Standalone

Further Reading

For comprehensive analyses, see our Sermorelin Research Guide | CJC-1295 No DAC Guide | CJC-1295 with DAC Guide

Also relevant: All GH Secretagogues Compared →

Written by NorthPeptide Research Team